Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DILOR vs AEROLONE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
DILOR (dyphylline) is a xanthine bronchodilator that inhibits phosphodiesterase, increasing intracellular c AMP levels, leading to relaxation of bronchial smooth muscle and suppression of airway responsiveness to stimuli. It also exhibits anti-inflammatory effects and enhances mucociliary clearance. Unlike theophylline, dyphylline is not converted to theophylline in vivo.
Selective beta2-adrenergic receptor agonist that relaxes bronchial smooth muscle by increasing cyclic AMP production via adenylate cyclase activation.
FDA-approved: Relief of acute bronchial asthma and reversible bronchospasm associated with chronic bronchitis and emphysema.,Off-label: Treatment of apnea of prematurity (limited use).
Treatment of bronchospasm in patients with COPD,Long-term maintenance treatment of asthma
DILOR (Dyphylline) 200-400 mg orally every 6 hours; maximum 1.6 g/day. Also available as IM injection: 250-500 mg every 6 hours.
AEROLONE is not a recognized drug; no standard dosing available.
Terminal elimination half-life is 3-4 hours in adults; may be prolonged in neonates, elderly, and patients with hepatic or cardiac dysfunction. Theophylline is a narrow therapeutic index drug; half-life dictates dosing frequency and need for therapeutic drug monitoring.
Terminal elimination half-life is approximately 12-15 hours in adults; prolonged to 24-30 hours in severe renal impairment (Cr Cl <30 m L/min).
Dyphylline is primarily metabolized by the liver via oxidation, with a smaller portion undergoing N-demethylation and oxidation. It is not metabolized to theophylline. Approximately 80% of the dose is excreted unchanged in the urine, indicating minimal hepatic metabolism.
Primarily metabolized by CYP3A4 and to a lesser extent CYP2D6, with conjugation to inactive metabolites.
Renal: approximately 50% unchanged drug; biliary/fecal: minimal (less than 10%). The remainder undergoes hepatic metabolism.
Primarily renal excretion of unchanged drug (approximately 65%) and hepatic metabolism (35%), with metabolites excreted in urine and feces. Biliary/fecal elimination accounts for <10%.
Approximately 40% bound to plasma proteins, primarily albumin.
Approximately 88% bound, primarily to albumin and alpha-1-acid glycoprotein.
0.3-0.7 L/kg, approximating total body water; higher in neonates and patients with decreased protein binding (e.g., hepatic disease).
3.5-5.0 L/kg, indicating extensive extravascular distribution and tissue binding.
Oral immediate-release: 100% (well absorbed); Extended-release formulations have comparable bioavailability with slower absorption.
Oral: 35-50% (first-pass metabolism); Inhalation: 15-30% (dependent on device and technique); Intravenous: 100%.
Cr Cl 50-80 m L/min: 75% of dose; Cr Cl 25-50 m L/min: 50% of dose; Cr Cl <25 m L/min: 25% of dose; hemodialysis: administer after dialysis at 50% of dose.
No data; not applicable.
No specific Child-Pugh based adjustments established; use with caution in severe hepatic impairment due to potential reduced clearance.
No data; not applicable.
Not recommended for use in children; safety and efficacy not established. If used: 3-5 mg/kg orally every 6 hours, titrate to serum levels.
No data; not applicable.
Start at lower end of dosing (200 mg every 6 hours) due to potential age-related decline in renal function; monitor serum levels and adjust based on Cr Cl.
No data; not applicable.
None
None
Use with caution in patients with peptic ulcer disease, hyperthyroidism, glaucoma, diabetes mellitus, severe hypoxemia, hypertension, arrhythmias, congestive heart failure, and renal impairment. Monitor serum levels; toxicity can occur at high doses. Concurrent use with other xanthines may increase toxicity. May cause seizures, arrhythmias, and death if serum levels exceed the therapeutic range.
Paradoxical bronchospasm,Cardiovascular effects (e.g., increased heart rate, QT prolongation),Hypokalemia,Hyperglycemia
Hypersensitivity to dyphylline or any component of the formulation; history of seizure disorder (unless adequately controlled); active gastrointestinal hemorrhage; concurrent use of other xanthine derivatives (e.g., theophylline, caffeine).
Hypersensitivity to arformoterol or any component of the formulation
Avoid large amounts of caffeine-containing foods/beverages (coffee, tea, cola, chocolate) as they may increase the risk of side effects like nervousness and palpitations. No other significant food interactions.
No significant food interactions. Avoid grapefruit juice as it may affect metabolism of the corticosteroid component.
DILOR (diprophylline) is a xanthine derivative. Animal studies have not shown teratogenic effects. There are no adequate and well-controlled studies in pregnant women. Risk cannot be ruled out. Fetal risks are considered low, but caution is advised during all trimesters.
No evidence of teratogenicity in animal studies at doses up to 10 mg/kg/day (approximately 120 times the maximum recommended human daily inhaled dose). In humans, no controlled studies exist; however, data from postmarketing reports do not suggest an increased risk of structural anomalies. First trimester: limited data preclude definitive risk assessment, but no pattern of major birth defects has emerged. Second and third trimesters: no known fetal harm from inhaled doses; however, potential for fetal adrenal suppression with prolonged high-dose systemic exposure.
Diprophylline is excreted into human milk. The M/P ratio is unknown. Potential adverse effects in infants include irritability and poor feeding. Weigh benefits against risks. Consider alternative bronchodilators if possible.
Unknown whether fluticasone propionate is excreted in human breast milk. Other corticosteroids are excreted in breast milk in low amounts, and inhaled doses result in negligible systemic levels, predicting unlikely significant infant exposure. M/P ratio not determined. Caution advised; weigh risk of maternal obstructive airway disease exacerbation against potential infant risks (adrenal suppression, growth retardation).
No specific dose adjustments recommended due to pregnancy. Pharmacokinetic changes in pregnancy may decrease drug clearance; monitor clinical response and adjust dose if needed based on efficacy and toxicity.
No specific dose adjustment required based on pharmacokinetic changes; pregnancy may cause decreased airway reactivity but no significant changes in fluticasone clearance. Maintain lowest effective dose to control asthma. No dose increase recommended solely due to pregnancy. Monitor asthma control and adjust dose as per standard guidelines.
DILOR (diprophylline) is a xanthine bronchodilator less potent than theophylline but with fewer GI side effects; monitor for nausea, tremor, tachycardia; use with caution in patients with peptic ulcer, hyperthyroidism, or seizure disorders; drug interactions include cimetidine, fluoroquinolones, and oral contraceptives which decrease clearance; theophylline levels are not routinely measured but toxicity can occur at high doses.
AEROLONE is a combination inhaler containing an inhaled corticosteroid (fluticasone propionate) and a long-acting beta2-agonist (salmeterol). Advise patients to rinse mouth with water after each use to reduce risk of oral candidiasis. Not for acute bronchospasm; use a rescue inhaler (short-acting beta agonist) as needed. Monitor for increased heart rate, palpitations, or tremor. Do not stop abruptly; taper dose under medical supervision if discontinuing.
Take exactly as prescribed; do not double doses.,Report persistent nausea, vomiting, rapid heartbeat, or chest pain.,Avoid excessive caffeine (coffee, tea, cola, chocolate) as it may increase side effects.,Inform all healthcare providers you are taking this medication.,Do not stop abruptly without consulting your doctor.,Store at room temperature away from heat and moisture.
Use AEROLONE exactly as prescribed; do not exceed recommended dose.,Rinse your mouth with water after each use (do not swallow) to prevent thrush.,This medication is not for sudden breathing problems; always keep your rescue inhaler (e.g., albuterol) with you.,Do not stop using this medicine without talking to your doctor, as stopping suddenly may worsen your breathing.,Seek immediate medical help if you experience worsening asthma, chest pain, or allergic reaction.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DILOR vs AEROLONE, answered by our medical review team.
DILOR is a Bronchodilator that works by DILOR (dyphylline) is a xanthine bronchodilator that inhibits phosphodiesterase, increasing intracellular c AMP levels, leading to relaxation of bronchial smooth muscle and suppression of airway responsiveness to stimuli. It also exhibits anti-inflammatory effects and enhances mucociliary clearance. Unlike theophylline, dyphylline is not converted to theophylline in vivo.. AEROLONE is a Bronchodilator that works by Selective beta2-adrenergic receptor agonist that relaxes bronchial smooth muscle by increasing cyclic AMP production via adenylate cyclase activation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DILOR and AEROLONE depend on the specific clinical indication. These are both Bronchodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DILOR is: DILOR (Dyphylline) 200-400 mg orally every 6 hours; maximum 1.6 g/day. Also available as IM injection: 250-500 mg every 6 hours.. The standard adult dose of AEROLONE is: AEROLONE is not a recognized drug; no standard dosing available.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DILOR and AEROLONE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DILOR is classified as Category C. DILOR (diprophylline) is a xanthine derivative. Animal studies have not shown teratogenic effects. There are no adequate and well-controlled studies in pregnant women. Risk cannot . AEROLONE is classified as Category C. No evidence of teratogenicity in animal studies at doses up to 10 mg/kg/day (approximately 120 times the maximum recommended human daily inhaled dose). In humans, no controlled stu. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.